West Building / Hangzhou SHARPLY Pharmaceutical Research Institute / Jintai Commercial Building / building No2 / N/A Production Building Building / /
IndustryTerm
quality management / aseptic manufacturing steps / treatment of HIV / Quality risk management / dedicated equipment / defective products / manufacturing buildings / manufacturing practices / risk management / manufacturing site / manufacturing / Deviation management / media fills / water systems / Manufacturing processes / e.g. manufacturing / /
MedicalCondition
HIV / sterility / /
Organization
State Food and Drug Administration / World Health Organization / Manufacturer Hainan Poly Pharma Co. Ltd Unit / Quality Department / US Food and Drug Administration / / /
Position
Quality director / General information Name / Summary General / Major / /
Product
date of inspection / mannitol / Product / products / materials / /
ProvinceOrState
Hainan Province / Zhejiang Province / Binjiang District / /
20, avenue Appia – CH-1211 Geneva 27 – Switzerland – Tel central +[removed] – Fax central +[removed] – www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) of the FPP manufacturer Part 1: General inform